Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer

Introduction: Having the Recurrence Score (RS) result using the Oncotype DX test (21-gene assay) for patients with node-positive (N1, 1-3 nodes) and a subset of node-negative tumours (intermediate clinical risk, and patients with grade 2, T1c tumours) can help reduce both harmful under- and over-treatment with chemotherapy. The cost-effectiveness of the Oncotype DX test in this combined population was assessed from an NHS and personal social services perspective.